Published on 27 May 2024 on Zacks via Yahoo Finance
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its investigational antibody, petosemtamab and Merck’s blockbuster oncology drug Keytruda.
This study evaluated the petosemtamab/Keytruda combination as a first-line treatment for patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).